{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:13:26Z","timestamp":1714436006092},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>The incidence of drug-resistant forms of tuberculosis (DR-TB) and the number of children treated with second-line drugs (SLDs) are increasing. However, limited amount of information is available regarding the use of SLDs in this population.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>To describe the treatment of pediatric TB with SLDs and factors associated with use of SLDs in children with and without documented DR-TB, records of pediatric TB patients referred to a center in Italy from 2007 to 2018 were reviewed retrospectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Of 204 children diagnosed with active TB during the study period, 42 were treated with SLDs because of confirmed or probable drug resistance (42.8%), adverse reactions to first-line drugs (7.1%), central nervous system involvement (11.9%) or unconfirmed possible drug resistance (38.1%). There were no deaths or adverse reactions to SLDs reported. Treatment was successful in 85.2% children treated with first-line drugs and 92.9% children treated with SLDs. After adjusting for calendar period, the only factor associated with DR-TB was &lt;2 years old [odds ratio (OR): 5.24 for &lt;2 years vs. 5\u201318 years; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.008]. Factors associated with treatment with SLDs were TB at 2 or more sites (OR: 11.30; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001), extrapulmonary TB (OR: 8.48; <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001) or adverse reactions to first-line drugs (OR: 7.48; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.002). No differences were noted in age or region of origin.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>A substantial proportion of TB children were treated with SLDs. The main reason for using SLDs was failure of a first-line drug regimen, suggesting possible DR-TB and underestimation of DR-TB in children. The use of SLD regimens was associated with a high success rate and good tolerability profile.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000002410","type":"journal-article","created":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T22:08:21Z","timestamp":1565302101000},"page":"1027-1034","source":"Crossref","is-referenced-by-count":0,"title":["Use of Second-line Medications and Treatment Outcomes in Children With Tuberculosis in a Single Center From 2007 to 2018"],"prefix":"10.1097","volume":"38","author":[{"given":"Elena","family":"Chiappini","sequence":"first","affiliation":[{"name":"From the Department of Health Sciences, Anna Meyer Children University Hospital, University of Florence, Florence, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tommaso","family":"Matucci","sequence":"additional","affiliation":[{"name":"From the Department of Health Sciences, Anna Meyer Children University Hospital, University of Florence, Florence, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catiuscia","family":"Lisi","sequence":"additional","affiliation":[{"name":"From the Department of Health Sciences, Anna Meyer Children University Hospital, University of Florence, Florence, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Petrolini","sequence":"additional","affiliation":[{"name":"From the Department of Health Sciences, Anna Meyer Children University Hospital, University of Florence, Florence, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Venturini","sequence":"additional","affiliation":[{"name":"From the Department of Health Sciences, Anna Meyer Children University Hospital, University of Florence, Florence, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Tersigni","sequence":"additional","affiliation":[{"name":"From the Department of Health Sciences, Anna Meyer Children University Hospital, University of Florence, Florence, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"de Martino","sequence":"additional","affiliation":[{"name":"From the Department of Health Sciences, Anna Meyer Children University Hospital, University of Florence, Florence, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Galli","sequence":"additional","affiliation":[{"name":"From the Department of Health Sciences, Anna Meyer Children University Hospital, University of Florence, Florence, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-20240429","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.pcl.2017.03.010","article-title":"Tuberculosis in children.","volume":"64","author":"Thomas","year":"2017","journal-title":"Pediatr Clin North Am"},{"key":"R3-20240429","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3201\/eid2503.180852","article-title":"Treatment Outcomes in Global Systematic Review and Patient Meta-Analysis of Children with Extensively Drug-Resistant Tuberculosis.","volume":"25","author":"Osman","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"R4-20240429","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1183\/13993003.01844-2015","article-title":"Tuberculosis in migrants from 106 countries to Italy, 2008\u20132015.","volume":"47","author":"Fattorini","year":"2016","journal-title":"Eur Respir J"},{"key":"R6-20240429","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1473-3099(17)30247-5","article-title":"Estimating the future burden of multidrug-resistant and extensively drug-resistant tuberculosis in India, the Philippines, Russia, and South Africa: a mathematical modelling study.","volume":"17","author":"Sharma","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"R7-20240429","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/resp.13304","article-title":"Drug-resistant tuberculosis: an update on disease burden, diagnosis and treatment.","volume":"23","author":"Lange","year":"2018","journal-title":"Respirology"},{"key":"R9-20240429","doi-asserted-by":"crossref","first-page":"e1002591","DOI":"10.1371\/journal.pmed.1002591","article-title":"Treatment and outcomes in children with multidrug-resistant tuberculosis: a systematic review and individual patient data meta-analysis.","volume":"15","author":"Harausz","year":"2018","journal-title":"PLoS Med"},{"key":"R10-20240429","doi-asserted-by":"crossref","first-page":"e5347","DOI":"10.1097\/MD.0000000000005347","article-title":"Efficacy, safety, and tolerability of a 24-month treatment regimen including delamanid in a child with extensively drug-resistant tuberculosis: a case report and review of the literature.","volume":"95","author":"Esposito","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"R11-20240429","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1517\/14656566.2015.1080240","article-title":"Bedaquiline and delamanid in tuberculosis.","volume":"16","author":"Esposito","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"R12-20240429","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3390\/ijms17030373","article-title":"Carbapenems to treat multidrug and extensively drug-resistant tuberculosis: a systematic review.","volume":"17","author":"Sotgiu","year":"2016","journal-title":"Int J Mol Sci"},{"key":"R13-20240429","doi-asserted-by":"crossref","first-page":"474","DOI":"10.5588\/ijtld.15.0666","article-title":"Treating children for drug-resistant tuberculosis in Tajikistan with group 5 medications.","volume":"20","author":"Swaminathan","year":"2016","journal-title":"Int J Tuberc Lung Dis"},{"key":"R14-20240429","doi-asserted-by":"crossref","first-page":"6073","DOI":"10.1128\/AAC.01404-15","article-title":"Pharmacokinetics and safety of ofloxacin in children with drug-resistant tuberculosis.","volume":"59","author":"Garcia-Prats","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"R15-20240429","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/cid\/ciu868","article-title":"Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis.","volume":"60","author":"Thee","year":"2015","journal-title":"Clin Infect Dis"},{"key":"R16-20240429","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/INF.0000000000002093","article-title":"Linezolid-containing treatment regimens for tuberculosis in children.","volume":"38","author":"Prieto","year":"2019","journal-title":"Pediatr Infect Dis J"},{"key":"R17-20240429","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.21037\/jtd.2017.06.16","article-title":"Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review.","volume":"9","author":"D\u2019Ambrosio","year":"2017","journal-title":"J Thorac Dis"},{"key":"R18-20240429","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/ppul.22755","article-title":"Moxifloxacin for the treatment of pulmonary tuberculosis in children: a single center experience.","volume":"49","author":"Garazzino","year":"2014","journal-title":"Pediatr Pulmonol"},{"key":"R19-20240429","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1097\/INF.0000000000001532","article-title":"Serious adverse reactions from anti-tuberculosis drugs among 599 children hospitalized for tuberculosis.","volume":"36","author":"Li","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"R20-20240429","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1378\/chest.128.3.1406","article-title":"Levofloxacin treatment of active tuberculosis and the risk of adverse events.","volume":"128","author":"Marra","year":"2005","journal-title":"Chest"},{"key":"R21-20240429","doi-asserted-by":"crossref","first-page":"e1253","DOI":"10.1542\/peds.2009-2172","article-title":"Two pediatric cases of multidrug-resistant tuberculosis treated with linezolid and moxifloxacin.","volume":"126","author":"Pinon","year":"2010","journal-title":"Pediatrics"},{"key":"R22-20240429","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1590\/0037-8682-0465-2016","article-title":"The importance of audiometric monitoring in patients with multidrug-resistant tuberculosis.","volume":"50","author":"Vasconcelos","year":"2017","journal-title":"Rev Soc Bras Med Trop"},{"key":"R23-20240429","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jinf.2012.09.002","article-title":"Hearing loss in children treated for multidrug-resistant tuberculosis.","volume":"66","author":"Seddon","year":"2013","journal-title":"J Infect"},{"key":"R24-20240429","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1136\/thoraxjnl-2013-203900","article-title":"High treatment success in children treated for multidrug-resistant tuberculosis: an observational cohort study.","volume":"69","author":"Seddon","year":"2014","journal-title":"Thorax"},{"key":"R25-20240429","doi-asserted-by":"crossref","DOI":"10.1007\/s12098-018-02846-8","article-title":"Diagnosis and management of multidrug-resistant tuberculosis in children: a practical approach.","author":"Schaaf","year":"2019","journal-title":"Indian J Pediatr"},{"key":"R26-20240429","doi-asserted-by":"crossref","first-page":"960","DOI":"10.3390\/ijms17060960","article-title":"Pediatric tuberculosis in Italian children: epidemiological and clinical data from the Italian register of pediatric tuberculosis.","volume":"17","author":"Galli","year":"2016","journal-title":"Int J Molec Sci"},{"key":"R27-20240429","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3855\/jidc.3950","article-title":"Demographic and microbial characteristics and drug resistance of childhood tuberculosis in Istanbul: analysis of 1,541 cases.","volume":"8","author":"Cakir","year":"2014","journal-title":"J Infect Dev Ctries"},{"key":"R28-20240429","first-page":"385","article-title":"Overcoming challenges in the diagnosis, prevention, and treatment of pediatric drug-resistant tuberculosis.","volume":"11","author":"Jonckheree","year":"2017","journal-title":"Expert Rev Respir Med"},{"key":"R29-20240429","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1473-3099(12)70033-6","article-title":"Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis.","volume":"12","author":"Ettehad","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"R30-20240429","doi-asserted-by":"crossref","first-page":"pii: E960","DOI":"10.3390\/ijms17060960","article-title":"Pediatric tuberculosis in Italian children: epidemiological and clinical data from the Italian register of pediatric tuberculosis.","volume":"17","author":"Galli","year":"2016","journal-title":"Int J Mol Sci"},{"key":"R31-20240429","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.cmi.2016.10.008","article-title":"Clinical management of adults and children with MDR and XDR-TB.","volume":"23","author":"Dheda","year":"2016","journal-title":"Clin Microbiol Inf"},{"key":"R32-20240429","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5588\/ijtld.17.0357","article-title":"The burden of multidrug-resistant tuberculosis in children.","volume":"22","author":"Jenkins","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"R33-20240429","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.5588\/ijtld.17.0911","article-title":"Tuberculosis in children treated with second-line drugs under programmatic conditions in Lima, Peru.","volume":"22","author":"Villarreal","year":"2018","journal-title":"Int J Tuberc Lung Dis"},{"key":"R34-20240429","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.phrs.2016.01.020","article-title":"Recommendations for treating children with drug-resistant tuberculosis.","volume":"105","author":"Galli","year":"2016","journal-title":"Pharmacol Res"},{"key":"R35-20240429","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tube.2016.01.004","article-title":"Safety and efficacy of additional levofloxacin in tuberculous meningitis: a randomized controlled pilot study.","volume":"98","author":"Kalita","year":"2016","journal-title":"Tuberculosis (Edinb)"},{"key":"R36-20240429","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1093\/jac\/dku103","article-title":"Safety and efficacy of levofloxacin versus rifampicin in tuberculous meningitis: an open-label randomized controlled trial.","volume":"69","author":"Kalita","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"R37-20240429","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ijantimicag.2014.12.027","article-title":"Pharmacokinetic\/pharmacodynamic analysis of an intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis.","volume":"45","author":"Te Brake","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"R38-20240429","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/INF.0000000000001114","article-title":"Linezolid is associated with improved early outcomes of childhood tuberculous meningitis.","volume":"35","author":"Li","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"R40-20240429","doi-asserted-by":"crossref","first-page":"132","DOI":"10.4103\/ijmy.ijmy_65_17","article-title":"Extrapulmonary tuberculosis in Colombian children: epidemiological and clinical data in a reference hospital.","volume":"6","author":"Sepulveda","year":"2017","journal-title":"Int J Mycobacteriol"},{"key":"R41-20240429","first-page":"289","article-title":"La tuberculose a` Abidjan: comparaison entre l\u2019enfant et l\u2019adulte.","volume":"24","author":"Cardenat","year":"2014","journal-title":"Med Sante Trop"},{"key":"R42-20240429","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1186\/s12889-018-5252-9","article-title":"Complementary surveillance strategies are needed to better characterise the epidemiology, care pathways and treatment outcomes of tuberculosis in children.","volume":"18","author":"du Preez","year":"2018","journal-title":"BMC Public Health"},{"key":"R43-20240429","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1097\/INF.0000000000000403","article-title":"Evaluation of the Xpert MTB\/RIF assay in gastric lavage aspirates for diagnosis of smear-negative childhood pulmonary tuberculosis.","volume":"33","author":"Pang","year":"2014","journal-title":"Pediatr Infect Dis J"},{"key":"R44-20240429","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/ppul.22970","article-title":"GeneXpert MTB\/RIF on bronchoalveolar lavage samples in children with suspected complicated intrathoracic tuberculosis: a pilot study.","volume":"49","author":"Walters","year":"2014","journal-title":"Pediatr Pulmonol"},{"key":"R45-20240429","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ijmyco.2016.02.004","article-title":"High prevalence of multidrug-resistant tuberculosis among patients with rifampicin resistance using GeneXpert Mycobacterium tuberculosis\/rifampicin in Ghana.","volume":"5","author":"Boakye-Appiah","year":"2016","journal-title":"Int J Mycobacteriol"},{"key":"R46-20240429","doi-asserted-by":"crossref","first-page":"e0169798","DOI":"10.1371\/journal.pone.0169798","article-title":"Diagnostic accuracy of GeneXpert MTB\/RIF assay in comparison to conventional drug susceptibility testing method for the diagnosis of multidrug-resistant tuberculosis.","volume":"12","author":"Pandey","year":"2017","journal-title":"PLoS One"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002410","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T18:08:15Z","timestamp":1714414095000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002410"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000002410","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]}}}